Status:
COMPLETED
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
Lead Sponsor:
Vitreo-Retinal Associates, Michigan
Collaborating Sponsors:
Van Andel Research Institute
Conditions:
Exudative Macular Degeneration
Diabetic Macular Edema
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Eligibility Criteria
Inclusion
- Male or female age 18 to 85 with diabetes and hemoglobin A1C \</= 10, or exudative macular degeneration.
- Diabetic macular edema with average retinal thickness central subfield \>/= 290um.
Exclusion
- Macular atrophy/fibrosis.
- Ocular anti-VEGF treatment within 3 months.
- Treatment with topical or oral carbonic-anhydrase inhibitor within one month
- Laser photocoagulation within 3 months (diabetic cohort)
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01473251
Start Date
November 1 2011
End Date
April 1 2014
Last Update
December 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitreo-Retinal Associates
Grand Rapids, Michigan, United States, 49525